Press enter to see results or esc to cancel.

Digital Health Exit Candidates

The list of potential digital health exit candidates is based on a number of criteria such as the amount of money raised, competitors that went public, notable partnerships and clients, growth figures, and more. Included are both SPAC candidates as well as those that could have their exit through a traditional IPO or in an M&A deal.

Headspace Health

🏦 Potential exit path: SPAC, IPO
Headquarters: Santa Monica, California, United States
Category: Mental Health
Funding Amount: $215.9M 🦄
Select investors: The Chernin Group, Spectrum Equity, Deerfield Management, Allen & Company, Advancit Capital, Jessica Alba, Jared Leto, Broadway Video Ventures, Freelands Ventures
Headspace Health was created by merging Ginger and Headspace with the goal of offering the world's most accessible and comprehensive digital mental health and wellbeing platform. Headspace is known for being one of the first meditation apps in the world and remains a leader in mindfulness and mental training. On the other hand, Ginger offers its members convenient, high-quality mental healthcare — including behavioral health coaching, therapy, and psychiatry — right from a smartphone. Together as Headspace Health, the two companies will serve consumers, employers, and health plans. Their combined expertise in consumer brand, evidence-based interventions, and technology will help improve resilience, reduce stress, and provide treatment to the millions of people experiencing mental health symptoms, from anxiety to depression to more complex diagnoses. more »

Maven Clinic

🏦 Potential exit path: SPAC, IPO
Headquarters: New York, New York, United States
Category: Women's Health
Funding Amount: $202.1M 🦄
💸 Last round (Series D) worth $110M was raised on August 17, 2021. at valuation of $1B+
Select investors: Dragoneer Investment Group, Lux Capital, Sequoia Capital, Oak HC/FT, Icon Ventures, Natalie Portman, Oprah Winfrey
Founded in 2014, Maven is the largest virtual clinic for women's and family health — offering continuous, holistic care for fertility, pregnancy and parenting. It has built the largest and most diverse network of practitioners, representing more than 30 specialties and 350 subspecialties across women's and family health. Maven has also built the largest team of Care Advocates in its category. Maven's digital programs are trusted by leading employers and health plans to reduce costs and drive better health outcomes for both parents and children. The company has supported more than 10 million women and families to date. Maven's model has been externally validated to drive better clinical outcomes, including lower NICU admissions and unnecessary c-section rates when compared to national averages. more »

Reify Health

🏦 Potential exit path: SPAC, IPO
Headquarters: Boston, Massachusetts, United States
Category: Clinical Trials
Funding Amount: $259.6M
💸 Last round (Series C) worth $220M was raised on August 10, 2021. at valuation of $2.2B
Select investors: Coatue Management, Battery Ventures, Sierra Ventures, Adams Street Partners, ICONIQ Growth
Reify Health has built a new foundation for how clinical trials are run through its business entities, StudyTeam and Care Access. The former is a cloud-based software that helps clinical trial teams achieve faster, more predictable enrollment while eliminating the tedious work that saps productivity and study budget. StudyTeam gives sponsors, CROs, and clinical research sites earlier visibility to the full enrollment picture, and the insight they need to focus people and capital on work that yields the greatest return. The result is faster enrollment, stronger relationships between sponsors and investigator sites, and higher return on R&D investment. On the other hand, Care Access is dubbed the world's leading decentralized research organization that brings clinical trial infrastructure directly to patients, healthcare providers, and communities. more »

Exo Imaging

🏦 Potential exit path: SPAC, IPO, M&A
Headquarters: Redwood City, California, United States
Category: Imaging
Funding Amount: $307.6M
💸 Last round (Series C) worth $220M was raised on August 2, 2021.
Select investors: RA Capital Management, Action Potential Venture Capital, Applied Ventures, BlackRock, Bold Capital Partners, Creative Ventures, Intel Capital, OSF Ventures, Pura Vida Investments
Exo (pronounced "Echo") is pioneering a high-performance handheld ultrasound platform and AI for imaging and therapeutic applications. The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. By delivering easy-to-use, high quality medical imaging - Exo will empower healthcare professionals to make critical, real-time decisions that improve patient outcomes — bringing diagnostic-grade medical imaging to the pocket of every caregiver and clinician worldwide. more »


🏦 Potential exit path: SPAC, M&A
Headquarters: Boston, Massachusetts, United States
Category: Digital Therapeutics
Funding Amount: $143.6M
💸 Last round (Series C) worth $100M was raised on September 3, 2020.
Select investors: SoftBank Vision Fund, Sequoia Capital, Openspace Ventures, EDBI, Aviva Ventures
Biofourmis is developing clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. The company's Biovitals (FDA-cleared) AI-powered health analytics platform is made to predict clinical exacerbation in advance of a critical event, which is the backbone of its digital therapeutics' product pipeline across multiple therapeutic areas — including heart failure, oncology, acute coronary syndrome, COPD and chronic pain. more »
Disclaimer: We can not guarantee that the information on this page is 100% correct. more